Simvastatin modulates the Alzheimer's disease-related gene seladin-1

J Alzheimers Dis. 2012;28(2):297-301. doi: 10.3233/JAD-2011-111118.

Abstract

This work describes a novel mechanism of neuroprotection by simvastatin: the modulation of seladin-1, an enzyme involved in Alzheimer's disease. Genomic and proteomic studies in human neuronal cells showed seladin-1 production to be increased in a dose- and time-dependent manner by simvastatin. This was confirmed in mice by immunohistochemical and qRT-PCR studies.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anticholesteremic Agents / pharmacology*
  • Brain / drug effects
  • Brain / metabolism
  • Cell Line, Tumor
  • Dose-Response Relationship, Drug
  • Humans
  • Mice
  • Nerve Tissue Proteins / genetics
  • Nerve Tissue Proteins / metabolism*
  • Neuroblastoma / pathology
  • Oxidoreductases Acting on CH-CH Group Donors / genetics
  • Oxidoreductases Acting on CH-CH Group Donors / metabolism*
  • RNA, Messenger / metabolism
  • Simvastatin / pharmacology*
  • Time Factors
  • Up-Regulation / drug effects*

Substances

  • Anticholesteremic Agents
  • Nerve Tissue Proteins
  • RNA, Messenger
  • Simvastatin
  • Oxidoreductases Acting on CH-CH Group Donors
  • DHCR24 protein, human